TREATABLE MORTALITY IN GENITOURINARY SYSTEM DISEASE
Introduction: In recent years there has been an increase of the genitourinary system disease. For instance, according to the Global Burden of Disease data in 2019 about 404.61 million cases registered and 236,790 deaths. In addition, between 1990 to 2019, the mortality rate increased 2.4 times where the age-standardized death rate rose fr om 2.77 to 3.13 per 100,000 population.
The aim of our study to calculate the treatable mortality from genitourinary system disease in Kazakhstan.
Methods: The mortality data from genitourinary system disease was obtained from the Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan (https://stat.gov.kz). The data was generated based on criteria and indicators developed by countries of the Organization for Economic Co-operation and Development (OECD), which include: the number of deaths by age categories and causes of death. Data presented for the period from 2015 to 2021, disaggregated by the age group of 5 years.
Results: Treatable mortality from renal failure in the whole of the Kazakhstan increased from 6.76 to 11.14 per 100,000 population, in particular, the growth was more than three times higher in 2021 compared to 2015 in in six regions of Kazakhstan. In Kazakhstan, the high rate of treatable mortality from renal failure in 2021 was within 10 or more per 100,000 of the population in nine regions.
Conclusion: An analysis of international studies shows an increase in the burden of diseases from genitourinary system, therefore, there is a need to improve prevention and treatment activities, especially in regions wh ere there is an increase in treatable deaths.
Lyazzat Kosherbayeva1,2, http://orcid.org/0000-0001-8376-4345
Aizhan Samambayeva3, http://orcid.org/0000-0001-8600-7980
Nazgul Akhtaeva1, https://orcid.org/0000-0002-0835-9814
Kamshat Tolganbayeva1, https://orcid.org/ 0000-0003-2388-7110
Aziza Imamatdinova1, https://orcid.org/0000-0003-2233-4522
1 Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan;
2 Al-Farabi Kazakh National University, Almaty, Republic of Kazakhstan;
3 AYeconomics Research Centre S.L., Santiago de Compostela, Spain.
1. Akerla J., Pesonen J.S., Poyhonen A., Koskimaki J., Häkkinen J., Huhtala H., Auvinen A., Tammela T.L.J. Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. J Urol. 2022 Jun. 207(6):1285-1294. doi: 10.1097/JU.0000000000002450.
2. Assari S., Lankarani M.M. Income Gradient in Renal Disease Mortality in the United States. Front Med (Lausanne). 2017 Nov 6. 4:190. doi: 10.3389/fmed.2017.00190.
3. Avoidable mortality: OECD/Eurostat lists of preventable and treatable causes of death (January 2022 version). January 2022 https://www.oecd.org/health/health-systems/Avoidable-mortality-2019-Joint-OECD-Eurostat-List-preventable-treatable-causes-of-death.pdf (accessed 11.12.2022).
4. Baigenzhin A., Doskaliyev Z., Tuganbekova S., Zharikov S., Altynova S., Gaipov A. Organ Transplants in Kazakhstan // Exp Clin Transplant. 2015 Nov. 13 Suppl 3:4-6. doi: 10.6002/ect.tdtd2015.L5.
5. Dare A.J., Fu S.H., Patra J., Rodriguez P.S., Thakur J.S., Jha P. Million Death Study Collaborators. Renal failure deaths and their risk factors in India 2001-13: nationally representative estimates from the Million Death Study // Lancet Glob Health. 2017 Jan. 5(1):e89-e95. doi: 10.1016/S2214-109X(16)30308-4.
6. Fraser A., Paul M., Almanasreh N. et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay // Am J Med. 2006. 119(11):970-976. doi:10.1016/j.amjmed.2006.03.034
7. Galiabovitch E., Hansen D., Retegan C., McCahy P. Urinary tract stone deaths: data from the Australian and New Zealand Audits of Surgical Mortality // BJU Int. 2020 Nov. 126(5):604-609. doi: 10.1111/bju.15171.
8. López-de-Andrés A., Albaladejo-Vicente R., Palacios-Ceña D., Carabantes-Alarcon D., Zamorano-Leon J.J., de Miguel-Diez J., Lopez-Herranz M., Jiménez-García R. Time Trends in Spain from 2001 to 2018 in the Incidence and Outcomes of Hospitalization for Urinary Tract Infections in Patients with Type 2 Diabetes Mellitus // Int J Environ Res Public Health. 2020 Dec 16. 17(24):9427. doi: 10.3390/ijerph17249427.
9. Noa Eliakim-Raz, Tanya Babitch, Evelyn Shaw, Ibironke Addy, Irith Wiegand, Christiane Vank, et al. RESCUING Study Group, Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group) // Clinical Infectious Diseases, Volume 68, Issue 1, 1 January 2019, Pages 29–36, https://doi.org/10.1093/cid/ciy418. (accessed 11.12.2022).
10. OECD Health Statistics 2022 Definitions, Sources and Methods https://stats.oecd.org/index.aspx?queryid=96018 (accessed 11.12.2022).
11. Olatunde O., Windsor-Shellard B., Campbell A. Revised definition of avoidable mortality. UK Office for National Statistics; 2016. Available at https://www.ons.gov.uk/file?uri=/aboutus/whatwedo/statistics/consultationsandsurveys/allconsultationsandsurveys/reviewofavoidablemortalitydefinition/reviseddefinitionofavoidablemortalityandnewdefinitionforchildrenandyoungpeople.doc (accessed 11.12.2022).
12. Papanicolas I., Rajan D., Karanikolos M., Soucat A., Figueras J. editors. Health system performance assessment: a framework for policy analysis. Geneva: World Health Organization. 2022 (Health Policy Series, No. 57). Licence: CC BY-NC-SA 3.0 IGO.
13. Reichel H., Zee J., Tu C., Young E., Pisoni R.L., Stengel B., Duttlinger J., Lonnemann G., Robinson B.M., Pecoits-Filho R., Fliser D. Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study // Nephrol Dial Transplant. 2020 May 1;35(5):803-810. doi: 10.1093/ndt/gfz260.
14. Rutstein D.D., Berenberg W., Chalmers T.C., Child C.G., Fishman A.P., Perrin E.B. Measuring the quality of medical care. A clinical method // N Engl J Med. 1976. 294(11):582-588. doi:10.1056/NEJM197603112941104
15. Rysmakhanov M., Yelemessov A., Mussin N., et al. Pure 3-Dimensional Laparoscopic Living-Donor Nephrectomy: First Case In Kazakhstan // Exp Clin Transplant. 2020. 18(Suppl 1):68-69. doi:10.6002/ect.TOND-TDTD2019.P12
16. Statistics Canada. Table 13-10-0151-01 Deaths, by cause, Chapter XIV: Diseases of the genitourinary system (N00 to N99) DOI:https://doi.org/10.25318/1310015101-eng https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310015101 (accessed 11.12.2022).
17. Thomas B., Matsushita K., Abate K.H., et al. Global Cardiovascular and Renal Outcomes of Reduced GFR // J Am Soc Nephrol. 2017. 28(7):2167-2179. doi:10.1681/ASN.2016050562
18. Tocut M., Zohar I., Schwartz O., Yossepowitch O., Maor Y. Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins // BMC Infect Dis. 2022. 22(1):571. Published 2022 Jun 24. doi:10.1186/s12879-022-07538-5
19. Yang X., Chen H., Zheng Y., Qu S., Wang H., Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report // Front Public Health. 2022 Jul 27. 10:888205. doi: 10.3389/fpubh.2022.888205.
20. Zhu C., Wang D.Q., Zi H., Huang Q., Gu J.M., Li L.Y., Guo X.P., Li F., Fang C., Li X.D., Zeng X.T. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019 // Mil Med Res. 2021 Dec 9. 8(1):64. doi: 10.1186/s40779-021-00359-8.
Number of Views: 83
Category of articles:
Original articles
Bibliography link
Kosherbayeva L., Samambayeva A., Akhtaeva N., Tolganbayeva K., Imamatdinova A. Treatable mortality in genitourinary system disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 79-85. doi 10.34689/SH.2023.25.1.010 Кошербаева Л., Самамбаева А., Ахтаева Н., Толганбаева К., Имаматдинова А. Излечимая смертность при заболеваниях мочеполовой системы // Наука и Здравоохранение. 2023. 1(Т.25). С. 79-85. doi 10.34689/SH.2023.25.1.010Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS